Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.
Also called NCT07929350
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
- Registry
-
NCT07929350
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07929350. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-20 (anticipated); primary completion 2028-01-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Fuling Yunhua Granules
- Intervention (Drug)
- Dihuang Baoyuan Granules
- Intervention (Drug)
- Fuling Yunhua Granules Matched Placebo
- Intervention (Drug)
- Dihuang Baoyuan Granules Matched Placebo
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Metformin Matched Placebo
- Lead sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct07929350- Content hash
b3082974aa1421877e454bdb68c1790d08b8178f97db83aecf151987d0380447